Sonus Pharmaceutical - Worst Pharma Stocks of 2007
Company: Sonus Pharmaceutical
Starting stock price: $6.02
Ending stock price: $0.44
Percent Change: -92.69%
Details: Sonus was delivered a crushing blow in September. A Phase III study of the company's breast cancer therapy, Tocosol Paclitaxel, was found to be less effective and linked to more side effects than Taxol. Bayer Schering terminated it's partnership with Sonus on the drug in October. The company has since enlisted Ferghana Partners to help evaluate the company's "alternative strategies." Sonus has one other cancer drug in development.
Related Articles:
Sonus shares shattered on drug failure. Report
Sonus shares surge as FDA approves Phase III design. Report
More stories about Sonus Pharmaceutical
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: